The Development of Non-Invasive Diagnostic Tools in Bladder Cancer

References

• Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of bladder cancer. Med Sci. 2020;8(1):15. doi:10.3390/medsci8010015
   Google Scholar
• Wong MCS, Fung FDH, Leung C, et al. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep. 2018;8(1):1129. doi:10.1038/s41598-018-19199-z
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430–442. doi:10.1016/j.eururo.2009.06.028
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures 2021. Atlanta, Ga: American Cancer Society; 2021. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html. Accessed October 27, 2021.
   Google Scholar
• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 V.1.0, Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Lyon: International Agency for Research on Cancer; 2013.
   Google Scholar
• Cheung G, Sahai A, Billia M, et al. Recent advances in the diagnosis and treatment of bladder cancer. BMC Med. 2013;11(1). doi:10.1186/1741-7015-11-13
   PubMed Web of Science ®Google Scholar
• Fankhauser CD, Mostafid H. Prevention of bladder cancer incidence and recurrence: nutrition and lifestyle. Curr Opin Urol. 2018;28(1):88–92. doi:10.1097/MOU.0000000000000452
   PubMed Web of Science ®Google Scholar
• Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 2017;119(3):371–380. doi:10.1111/bju.13760
   PubMed Web of Science ®Google Scholar
• Truta A, Popon TA, Saraci G, et al. Novel non invasive diagnostic strategies in bladder cancer. Clujul Med. 2016;89(2):187–192. doi:10.15386/cjmed-534
   PubMedGoogle Scholar
• Smith AB, Jaeger B, Pinheiro LC, et al. Impact of bladder cancer on health-related quality of life. BJU Int. 2018;121(4):549–557. doi:10.1111/bju.14047
   PubMed Web of Science ®Google Scholar
• Anastasiadis A, de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol. 2012;4(1):13–32. doi:10.1177/1756287211431976
   PubMedGoogle Scholar
• Poli G, Cochetti G, Boni A, et al. Characterization of inflammasome-related genes in urine sediments of patients receiving intravesical BCG therapy. Urol Oncol. 2017;35(12):674.e19–674.e24. doi:10.1016/j.urolonc.2017.08.004
   PubMed Web of Science ®Google Scholar
• Soubra A, Risk MC. Diagnostics techniques in nonmuscle invasive bladder cancer. Indian J Urol. 2015;31(4):283–288. doi:10.4103/0970-1591.166449
   PubMedGoogle Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population- based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi:10.3322/caac.21388
   PubMed Web of Science ®Google Scholar
• Schroeck FR, Smith N, Shelton JB. Implementing risk-aligned bladder cancer surveillance care. Urol Oncol. 2018;36(5):257–264. doi:10.1016/j.urolonc.2017.12.016
   PubMed Web of Science ®Google Scholar
• Ng K, Stenzl A, Sharma A, Vasdev N. Urinary biomarkers in bladder cancer: a review of the current landscape and future directions. Urol Oncol. 2021;39(1):41–51. doi:10.1016/j.urolonc.2020.08.016
   PubMed Web of Science ®Google Scholar
• Yafi FA, Brimo F, Steinberg J, et al. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol. 2015;33(2):66.e25–31. doi:10.1016/j.urolonc.2014.06.008
   PubMed Web of Science ®Google Scholar
• Henning GM, Barashi NS, Smith ZL. Advances in biomarkers for detection, surveillance, and prognosis of bladder cancer. Clin Genitourin Cancer. 2021;19(3):194–198. doi:10.1016/j.clgc.2020.12.003
   PubMed Web of Science ®Google Scholar
• Chou R, Gore JL, Buckley D, et al. Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis. Ann Intern Med. 2015;163(12):922–931. doi:10.7326/M15-0997
   PubMed Web of Science ®Google Scholar
• Smith ZL, Guzzo TJ. Urinary markers for bladder cancer. F1000 Prime Rep. 2013;5. doi:10.12703/P5-21
   PubMedGoogle Scholar
• Raitanen M-P. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol. 2008;26:45–50. doi:10.1007/s00345-007-0230-3
   PubMed Web of Science ®Google Scholar
• Guo A, Wang X, Gao L, et al. Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: a meta-analysis. Can Urol Assoc J. 2014;8(5–6):E347–E352. doi:10.5489/cuaj.1668
   PubMed Web of Science ®Google Scholar
• Thomas L, Leyh H, Marberger M, et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem. 1999;45(4):472–477. doi:10.1093/clinchem/45.4.472
   PubMed Web of Science ®Google Scholar
• Nagai T, Naiki T, Etani T, et al. UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives. Transl Androl Urol. 2021;10(4):1908–1917. doi:10.21037/tau-20-1207
   PubMed Web of Science ®Google Scholar
• Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol. 2008;26(6):646–651. doi:10.1016/j.urolonc.2007.06.002
   PubMed Web of Science ®Google Scholar
• Lavery HJ, Zaharieva B, McFaddin A, et al. A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection. BMC Cancer. 2017;17(1):247. doi:10.1186/s12885-017-3227-3
   PubMed Web of Science ®Google Scholar
• Dimashkieh H, Wolff DJ, Smith TM, et al. Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol. 2013;121(10):591–597. doi:10.1002/cncy.21327
   PubMed Web of Science ®Google Scholar
• Moonen PM, Merkx GF, Peelen P, et al. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol. 2007;51(5):1275–80; discussion 1280. doi:10.1016/j.eururo.2006.10.044
   PubMed Web of Science ®Google Scholar
• Kim PH, Sukhu R, Cordon BH, et al. Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy. BJU Int. 2014;114:354–359.
   PubMed Web of Science ®Google Scholar
• Fradet Y, Lockhard C. Performance characteristics of a new monoclonal antibody test for bladder cancer: immunoCyt trademark. Can J Urol. 1997;4:400–405.
   PubMedGoogle Scholar
• Bhat A, Ritch CR. Urinary biomarkers in bladder cancer: where do we stand? Curr Opin Urol. 2019;29(3):203–209. doi:10.1097/MOU.0000000000000605
   PubMed Web of Science ®Google Scholar
• He H, Han C, Hao L, Zang G. ImmunoCyt test compared to cytology in the diagnosis of bladder cancer: a meta-analysis. Oncol Lett. 2016;12(1):83–88. doi:10.3892/ol.2016.4556
   PubMed Web of Science ®Google Scholar
• Oeyen E, Hoekx L, De Wachter S, et al. Bladder cancer diagnosis and follow-up: the current status and possible role of extracellular vesicles. Int J Mol Sci. 2019;20(4):821. doi:10.3390/ijms20040821
   PubMed Web of Science ®Google Scholar
• Wallace E, Higuchi R, Satya M, et al. Development of a 90-minute integrated noninvasive urinary assay for bladder cancer detection. J Urol. 2018;199:655–662. doi:10.1016/jjuro.2017.09.141
   PubMed Web of Science ®Google Scholar
• Valenberg FJ, Hiar AM, Wallace E, et al. Validation of an mRNA-based urine test for the detection of bladder cancer in patients with haematuria. Eur Urol Oncol. 2021;4(1):93–101. doi:10.1016/j.euo.2020.09.001
   PubMed Web of Science ®Google Scholar
• Pichler R, Fritz J, Tulchiner G, et al. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. BJU Int. 2018;121(1):29–37. doi:10.1111/bju.14019
   PubMed Web of Science ®Google Scholar
• Cancel-Tassin G, Roupret M, Pinar U, et al. Assessment of Xpert bladder cancer monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up. World J Urol. 2021;39(9):3329–3335. doi:10.1007/s00345-021-03629-1
   PubMed Web of Science ®Google Scholar
• Laukhtina E, Shim SR, Mori K, et al. Diagnostic accuracy of novel urinary biomarker tests in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis. Eur Urol Oncol. 2021;4(6):927–942. doi:10.1016/j.euo.2021.10.003
   PubMed Web of Science ®Google Scholar
• O’Sullivan P, Sharples K, Dalphin M, et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol. 2012;188(3):741–747. doi:10.1016/j.juro.2012.05.003
   PubMed Web of Science ®Google Scholar
• Lotan Y, O’Sullivan P, Raman JD, et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol. 2017;35(8):531.e15–531.e22. doi:10.1016/j.urolonc.2017.03.008
   Web of Science ®Google Scholar
• Koya M, Osborne S, Chemaslé C, et al. An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer. BMC Urol. 2020;20(1). doi:10.1186/s12894-020-0583-0
   PubMed Web of Science ®Google Scholar
• Wolfs JRE, Hermans TJN, Koldewijn EL, van de Kerkhof D. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: a review. Urol Oncol. 2021;39(3):161–170. doi:10.1016/j.urolonc.2020.11.014
   PubMed Web of Science ®Google Scholar
• Roupret M, Gontero P, McCracken SRC, et al. Diagnostic accuracy of MCM5 for the detection of recurrence in nonmuscle invasive bladder cancer followup: a blinded, prospective cohort, multicenter European study. J Urol. 2020;204(4):685–690. doi:10.1097/JU.0000000000001084
   PubMed Web of Science ®Google Scholar
• Dudderidge T, Stockley J, Nabi G, et al. A novel, non-invasive test enabling bladder cancer detection in urine sediment of patients presenting with haematuria-a prospective multicentre performance evaluation of ADXBLADDER. Eur Urol Oncol. 2020;3(1):42–46. doi:10.1016/j.euo.2019.06.006
   PubMed Web of Science ®Google Scholar
• Anastasi E, Maggi M, Tartaglione S, et al. Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: a comparative prospective study. Diagn Cytopathol. 2020;48:1034–1040. doi:10.1002/dc.24530
   PubMed Web of Science ®Google Scholar
• Beukers W, Kandimalla R, Masius R, et al. Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancer. Mod Pathol. 2015;28:515–522. doi:10.1038/modpathol.2014.145
   PubMed Web of Science ®Google Scholar
• Friedrich MG, Toma MI, Chun JK, et al. DNA-Methylierung in der Urindiagnostik und als Prognosemarker beim Urothelkarzinom der Harnblase [DNA methylation on urinalysis and as a prognostic marker in urothelial cancer of the bladder]. Urologe A. 2007;46(7):761–768. German. doi:10.1007/s00120-007-1360-3
   PubMedGoogle Scholar
• Mancini M, Righetto M, Zumerle S, et al. The bladder EpiCheck test as a non-invasive tool based on the identification of DNA methylation in bladder cancer cells in the urine: a review of published evidence. Int J Mol Sci. 2020;21(18):6542. doi:10.3390/ijms21186542
   PubMed Web of Science ®Google Scholar
• Wasserstrom A, Frumkin D, Dotan Z, et al. MP13-15 molecular urine cytology – bladder epicheck is a novel molecular diagnostic tool for monitoring of bladder cancer patients. J Urol. 2016;195:e140. doi:10.1016/j.juro.2016.02.2496
   PubMed Web of Science ®Google Scholar
• Witjes JA, Morote J, Cornel EB, et al. Performance of the bladder EpiCheck™ methylation test for patients under surveillance for non-muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial. Eur Urol Oncol. 2018;1(4):307–313. doi:10.1016/j.euo.2018.06.011
   PubMed Web of Science ®Google Scholar
• Cochetti G, Rossi de Vermandois JA, Maula V, et al. Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: a single centre, prospective, blinded clinical trial. Urol Oncol. 2021;S1078-1439(21)00483-X. doi:10.1016/j.urolonc.2021.11.001
   Web of Science ®Google Scholar
• Mezzasoma L, Antognelli C, Del Buono C, et al. Expression and biological-clinical significance of hTR, hTERT and CKS2 in washing fluids of patients with bladder cancer. BMC Urol. 2010;10:17. doi:10.1186/1471-2490-10-17
   PubMed Web of Science ®Google Scholar
• Descotes F, Kara N, Decaussin-Petrucci M, et al. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine. Br J Cancer. 2017;117:583–587. doi:10.1038/bjc.2017.210
   PubMed Web of Science ®Google Scholar
• Sieverink CA, Batista RPM, Prazeres HJM, et al. Clinical validation of a urine test (Uromonitor-V2®) for the surveillance of non-muscle-invasive bladder cancer patients. Diagnostics. 2020;10(10):745. doi:10.3390/diagnostics10100745
   Web of Science ®Google Scholar
• van Kessel KE, Van Neste L, Lurkin I, et al. Evaluation of an epigenetic profile for the detection of bladder cancer in patients with hematuria. J Urol. 2016;195(3):601–607. doi:10.1016/j.juro.2015.08.085
   PubMed Web of Science ®Google Scholar
• Slovin S, Carissimo A, Panariello F, et al. Single-cell RNA sequencing analysis: a step-by-step overview. Methods Mol Biol. 2021;2284:343–365. doi:10.1007/978-1-0716-1307-8_19
   PubMedGoogle Scholar
• Wang Z, Chen J, Yang L, et al. Single-cell sequencing-enabled hexokinase 2 assay for noninvasive bladder cancer diagnosis and screening by detecting rare malignant cells in urine. Anal Chem. 2020;92(24):16284–16292. doi:10.1021/acs.analchem.0c04282
   PubMed Web of Science ®Google Scholar
• Southgate J, Harnden P, Trejdosiewicz LK. Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications. Histol Histopathol. 1999;14:657–664. doi:10.14670/HH-14.657
   PubMed Web of Science ®Google Scholar
• Ecke TH, Weiß S, Stephan C, et al. UBC ® Rapid Test for detection of carcinoma in situ for bladder cancer. Tumor Biol. 2017;39:101042831770162. doi:10.1177/1010428317701624
   Google Scholar
• Puerta-Gil P, García-Baquero R, Jia AY, et al. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol. 2012;180(5):1808–1815. doi:10.1016/j.ajpath.2012.01.034
   PubMed Web of Science ®Google Scholar
• Gottardo F, Liu CG, Ferracin M, et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 2007;25:387–392. doi:10.1016/j.urolonc.2007.01.019
   PubMed Web of Science ®Google Scholar
• Yang H, Dinney CP, Ye Y, et al. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res. 2008;68:2530–2537. doi:10.1158/0008-5472.CAN-07-5991
   PubMed Web of Science ®Google Scholar
• Urquidi V, Netherton M, Gomes-Giacoia E, et al. A microRNA biomarker panel for the non-invasive detection of bladder cancer. Oncotarget. 2016;7(52):86290–86299. doi:10.18632/oncotarget.13382
   PubMedGoogle Scholar
• Elsharkawi F, Elsabah M, Shabayek M, Khaled H. Urine and serum exosomes as novel biomarkers in detection of bladder cancer. Asian Pac J Cancer Prev. 2019;20(7):2219–2224. doi:10.31557/APJCP.2019.20.7.2219
   PubMedGoogle Scholar
• Poli G, Egidi MG, Cochetti G, et al. Relationship between cellular and exosomal miRNAs targeting NOD-like receptors in bladder cancer: preliminary results. Minerva Urol Nefrol. 2020;72(2):207–213. doi:10.23736/S0393-2249.19.03297-1
   PubMed Web of Science ®Google Scholar
• MacGregor M, Shirazi HS, Chan KM, et al. Cancer cell detection device for the diagnosis of bladder cancer from urine. Biosens Bioelectron. 2021;171:112699. doi:10.1016/j.bios.2020.112699
   PubMed Web of Science ®Google Scholar
• Chan E, Pradere B, Teoh J, Chuna Y. The use of artificial intelligence for the diagnosis of bladder cancer: a review and perspectives. Curr Opin Urol. 2021;31(4):397–403. doi:10.1097/MOU.0000000000000900
   PubMed Web of Science ®Google Scholar
• Wu S, Chen X, Pan J, et al. An artificial intelligence system for the detection of bladder cancer via cystoscopy: a multicenter diagnostic study. J Natl Cancer Inst. 2022;114(2):220–227. doi:10.1093/jnci/djab179
   PubMedGoogle Scholar
• Halpern JA, Chughtai B, Ghomrawi H. Cost-effectiveness of common diagnostic approaches for evaluation of asymptomatic microscopic hematuria. JAMA Intern Med. 2017;177(6):800–807. doi:10.1001/jamainternmed.2017.0739
   PubMed Web of Science ®Google Scholar
• Zhu CZ, Ting HN, Ng KH, Ong TA. A review on the accuracy of bladder cancer detection methods. J Cancer. 2019;10(17):4038–4044. doi:10.7150/jca.28989
   PubMed Web of Science ®Google Scholar
• Zuiverloon T, de Jong F, Theodorescu D. Clinical decision making in surveillance of non–muscle-invasive bladder cancer: the evolving roles of urinary cytology and molecular markers. Cancer Network; 2017. Available from: https://www.cancernetwork.com/view/clinical-decision-making-surveillance-nonmuscle-invasive-bladder-cancer-evolving-roles-urinary. Accessed December 10, 2021.
   Google Scholar
• NICE. ADXBLADDER for detecting bladder cancer; 2019. Available from: https://www.nice.org.uk/advice/mib180/chapter/The-technology. Accessed December 10, 2021.
   Google Scholar
• Lotan Y, Gakis G, Manfredi M, et al. Alternating cystoscopy with bladder EpiCheck in the surveillance of low-grade intermediate-risk NMIBC: a cost comparison model. Bladder Cancer. 2021;7(3):307–315. doi:10.3233/BLC-211528
   Web of Science ®Google Scholar
• Benderska-Söder N, Hovanec J, Pesch B, et al. Toward noninvasive follow-up of low-risk bladder cancer - rationale and concept of the UroFollow trial. Urol Oncol. 2020;38(12):886–895. doi:10.1016/j.urolonc.2020.01.006
   PubMed Web of Science ®Google Scholar